Matarin Capital Management Lowers stake in USANA Health Sciences (USNA)

USANA Health Sciences (USNA) : Matarin Capital Management reduced its stake in USANA Health Sciences by 0.96% during the most recent quarter end. The investment management company now holds a total of 69,534 shares of USANA Health Sciences which is valued at $9,195,176 after selling 676 shares in USANA Health Sciences , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.USANA Health Sciences makes up approximately 1.18% of Matarin Capital Management’s portfolio.

Other Hedge Funds, Including , Blackrock Advisors boosted its stake in USNA in the latest quarter, The investment management firm added 7,982 additional shares and now holds a total of 22,007 shares of USANA Health Sciences which is valued at $2,910,206. Global X Management Co added USNA to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $13,501.Ifrah Financial Services reduced its stake in USNA by selling 1,593 shares or 39.67% in the most recent quarter. The Hedge Fund company now holds 2,423 shares of USNA which is valued at $333,938. USANA Health Sciences makes up approx 0.13% of Ifrah Financial Services’s portfolio. New Amsterdam Partnersny sold out all of its stake in USNA during the most recent quarter. The investment firm sold 110,080 shares of USNA which is valued $15,055,642.

USANA Health Sciences opened for trading at $133 and hit $134.19 on the upside on Friday, eventually ending the session at $133.53, with a gain of 0.94% or 1.25 points. The heightened volatility saw the trading volume jump to 76,642 shares. Company has a market cap of $1,607 M.

On the company’s financial health, USANA Health Sciences reported $1.77 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $1.81. The company had revenue of $240.45 million for the quarter, compared to analysts expectations of $244.05 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.50 EPS.

Many Wall Street Analysts have commented on USANA Health Sciences. Company shares were Reiterated by DA Davidson on Jul 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 150 from a previous price target of $135 .

USANA Health Sciences Inc. develops and manufactures science-based nutritional and personal care products. The Company has operations in approximately 19 markets across the world where it distributes and sells its products by way of direct selling. The Company operates as a direct selling company and reports revenue in two geographic regions: Americas and Europe and Asia Pacific which includes three sub-regions as: Southeast Asia Pacific Greater China and North Asia. Americas and Europe includes the United States Canada Mexico Colombia the United Kingdom France Belgium and the Netherlands. Southeast Asia Pacific includes Australia New Zealand Singapore Malaysia the Philippines and Thailand; Greater China includes Hong Kong Taiwan and China and North Asia includes Japan and South Korea.

Leave a Reply

USANA Health Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on USANA Health Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.